{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yao A"],"funding":["Jiangsu Provincial Science Fund for Distinguished Young Scholars","he National Natural Science Foundation of China"],"pagination":["750"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12103785"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["Background
A two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of INO-4800.Methods
Healthy adults who received two doses of INO-4800 (1.0 mg or 2.0 mg) at least 12 months ago in a previous phase 2 trial were eligible for this booster study, conducted in Danyang, Jiangsu Province, China. Eligible participants were stratified by primary vaccination dose (1.0 mg or 2.0 mg) and age group (18-59 years or ≥ 60 years), and subsequently randomized in a 1:1 ratio to receive a third dose of INO-4800 or placebo at the same dosage as previously administered. The prim"],"journal":["BMC infectious diseases"],"pubmed_title":["Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial."],"pmcid":["PMC12103785"],"funding_grant_id":["82341031, 82173584, and 82222062","BK20220064"],"pubmed_authors":["Yang H","Xia Y","Xu M","Li J","Leng D","Wang B","Cheng X","Wang J","Xu J","Pan H","Jia S","Huai X","Zhao G","Yao A","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial.","description":"Background
A two-dose primary regimen of INO-4800 DNA vaccine demonstrated only modest immunogenicity in the previous phase 2 clinical trial. This booster study aimed to evaluate the immunogenicity and safety of a booster dose of INO-4800 in adults previously received two-dose regimen of INO-4800.Methods
Healthy adults who received two doses of INO-4800 (1.0 mg or 2.0 mg) at least 12 months ago in a previous phase 2 trial were eligible for this booster study, conducted in Danyang, Jiangsu Province, China. Eligible participants were stratified by primary vaccination dose (1.0 mg or 2.0 mg) and age group (18-59 years or ≥ 60 years), and subsequently randomized in a 1:1 ratio to receive a third dose of INO-4800 or placebo at the same dosage as previously administered. The prim","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T02:43:40.634Z","creation":"2026-04-13T03:12:34.277Z"},"accession":"S-EPMC12103785","cross_references":{"pubmed":["40414851"],"doi":["10.1186/s12879-025-11140-w"]}}